Skip to content
Search

Latest Stories

GPhC Council to increase renewal fees by 7.5% from April 2024

The council declared a rise in the renewal fees for pharmacy workers starting next year

The General Pharmaceutical Council (GPhC) has decided to increase the renewal fees of pharmacists, pharmacy technicians, and pharmacy premises by 7.5% from April 2024.


The pharmacy technician's renewal fee will see an increase by £9 from £121 to £130, pharmacists fees from £257 to £276, and pharmacy premises from £365 to £392.

The following decision came even despite the renewal fees being frozen for individual registrants since 2019 and for pharmacy premises since 2021.

This move was facilitated through cost savings measures like using financial reserves and downsizing to a smaller office.

However, the council confirmed that the fee hike is due to higher rates of inflation, increase in utility bills and supplier costs.

Duncan Rudkin, Chief Executive and Registrar of the GPhC, said: “We know that these are challenging times and that this increase will come as unwelcome news to those we regulate. But to be effective in our role of protecting the public we need to make sure the fees we charge cover the cost of regulation going forward.”

Giving reasons for the fee rise, Rudkin stated that they are subject to the same “inflationary pressures and financial challenges” as those they regulate.

The Council concluded that it took the "difficult decision" to raise the fees in order to be in a position to continue to carry out regulatory work.

“We are working in a changing environment and have to adapt accordingly and regulate in a world where pharmacy is evolving at pace,” Rudkin said.

“This will continue to lead to significant changes in the scope and complexity of our work, on top of the major projects we are already undertaking such as reforms to initial education and training; post-registration assurance of practice, and the development of new standards following legislative change.

“In taking this difficult decision, we are ensuring we can carry out our statutory duties and continue to ensure patients and the public receive safe and effective pharmacy care and have trust in pharmacy, now and in the future,” he added.

The Council received 7129 responses to the consultation on fees, which closed on 8 August 2023, and many of them disagreed with the proposed increases.

Responding to the feedback on paying fees differently, the GPhC said that it will be “looking into the feasibility of offering a monthly direct debit option, in addition to the current option to pay by quarterly direct debit.”

In the near future, the GPhC is planning to move towards a more regular and incremental approach to fee setting to provide more certainty about future fees and enable any fee changes to be introduced more gradually in the future.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less